Heart Failure Research
Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.
Heart Failure Research Products Targets
- PI 3-kinase (22)
- Others (7)
- Mineralocorticoid Receptor (7)
- Angiotensin-Converting Enzyme (8)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- NKCC (2)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Heart Failure Research - Page 6
- Cat.No. Product Name Information/Activity
-
BCC6728
Spiroxatrine
1054-88-2
-
BCN6268
Yohimbine Hydrochloride
Yohimbine Hydrochloride is an alpha 2-adrenoreceptor antagonist, blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine.
-
BCC6813
Agmatine sulfate
Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor.
-
BCC6861
Xamoterol hemifumarate
73210-73-8
-
BCC6633
(S)-(-)-Atenolol
93379-54-5
-
BCC4343
Betaxolol HCl
Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.
-
BCC4344
Bisoprolol fumarate
(±)-Bisoprolol (hemifumarate) is a selective type β1 adrenergic receptor blocker.
-
BCC6893
CGP 20712 dihydrochloride
1216905-73-5
-
BCC4330
Metoprolol Tartrate
Metoprolol is a cardioselective β1-adrenergic blocking agent.
-
BCC4340
Timolol Maleate
(S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.


